ModifiedUnitedHealthcarePolicy CS2026D0081O

Sodium Hyaluronate (intra‑articular) for knee osteoarthritis

Medicaid medical benefit policy governing coverage and authorization criteria for intra‑articular sodium hyaluronate injections for knee osteoarthritis for UnitedHealthcare Community Plan members (state‑specific exceptions noted).

Policy Summary

PayerUnitedHealthcare

PolicySodium Hyaluronate (intra‑articular) for knee osteoarthritis

Policy CodePolicy CS2026D0081O

Change TypeState applicability update (Nebraska excluded)

Effective DateJan 1, 2026

Next Review Date

Key ActionSubmit prior authorization with documentation of diagnosis, ≥3 months of conservative therapy (or intolerance), and product-specific regimen to request coverage for a 6‑month course.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate this Medical Benefit Drug Policy does not apply to the state of Nebraska.

knee OA onlyIndication covered

6 monthsInitial auth length

≥6 monthsReauth interval

multipleFDA products listed

excluded

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Intra‑articular Sodium Hyaluronate

Initial Authorization (Sodium Hyaluronate‑Naïve Patients)

Covered when ALL of the following are met:

Initial authorization - all criteria: Diagnosis of knee osteoarthritis; and the member has not responded adequately to conservative therapy (eg, physical therapy or pharmacotherapy such as NSAIDs, acetaminophen, topical capsaicin) or intra‑articular steroid injection with no functional improvement after at least 3 months, or the member is unable to tolerate conservative therapy due to adverse effects; and the member reports pain which interferes with functional activities (eg, ambulation, prolonged standing); and the pain is attributed to degenerative joint disease/primary osteoarthritis of the knee; and there are no contraindications to injections (eg, active joint infection, bleeding disorder); and dosing is in accordance with FDA‑approved labeling for the selected product; and initial authorization is for a single injection course once per joint for 6 months.see nodes

Dosing per FDA labeled product-specific course (see reauthorization node).

Reauthorization/Continuation

Covered when ALL of the following are met:

Reauthorization - all criteria: Diagnosis of knee osteoarthritis; and documentation of positive clinical response to the prior hyaluronan injection course (eg, significant pain relief); and pain has recurred; and at least 6 months have passed since the prior course for the respective joint; and dosing is in accordance with FDA‑approved labeling for the selected product; and continuing authorization is for a single injection course once per joint for 6 months.>= 6 months since prior course

Positive clinical response example: significant pain relief achieved with prior course.

Preferred Product Criteria

Covered for specified products when ONE of the following two blocks is met:

Preferred product exceptions - option A: Both of the following: history of a trial of adequate dose and duration of Durolane, Euflexxa, and Gelsyn-3 resulting in minimal clinical response; and physician attests that, in their clinical opinion, the clinical response would be expected to be superior with the requested non‑preferred product.

Preferred product exceptions - option B: Both of the following: history of failure, contraindication, or intolerance to Durolane, Euflexxa, and Gelsyn-3; and physician attests that the same failure, contraindication, or intolerance would not be expected to occur with the requested non‑preferred product.

Coverage considerations by anatomic site

Coverage considerations by indication based on evidence presented in this section:

Shoulder (glenohumeral OA, rotator cuff pathology): Systematic reviews and RCTs report pain and function improvement after intra‑articular HA with rare adverse events; however, similar improvements in control groups and heterogeneity across trials limit definitive conclusions. Additional high‑quality RCTs are needed.evidence mixed but suggests possible benefit

Consider coverage when conservative therapy failed and patient‑specific factors favor HA; document prior treatments and shared decision‑making.

Hip OA: Evidence is inconsistent: some uncontrolled series suggest delayed progression in selected patients but a multicenter placebo RCT found no difference at 3 months (Richette et al.), and guidelines generally do not support routine use.not established

Generally not routinely covered unless compelling clinical rationale and documented failure of alternatives; require prior authorization.

Implied coverage criteria for knee OA and vocal fold medialization

Covered when ALL of the following are met (implied from FDA labeling and guideline context):

Knee OA, FDA‑labeled use: Patient has symptomatic osteoarthritis of the knee; has failed conservative therapy (eg, exercise and simple analgesics); the intended HA product and regimen match an FDA‑approved labeling (product‑specific injection counts as per labeling); and there are no contraindications to injections.per product labeling

FDA labeling specifies single‑ or multi‑injection regimens for specific products (eg, Hyalgan 5 injections; Synvisc 3; Synvisc One single; Gel‑One single; Monovisc single; Durolane single; etc.).

Injection laryngoplasty (temporary medialization): Use of cross‑linked or appropriately sized HA preparations for intracordal injection may be considered for temporary medialization (approximately 4–6 months) in unilateral vocal fold paralysis when medium‑term improvement is desired, with procedure performed by qualified specialists and documentation of voice impairment.~6 months durability reported

Evidence quality is limited; small RCTs and observational studies report improved voice measures and VHI but larger trials are needed.

Intra‑articular sodium hyaluronate injections are not medically necessary for indications outside of FDA‑labeled knee osteoarthritis use. The policy specifically lists hip osteoarthritis, temporomandibular joint osteoarthritis, and temporomandibular joint disc displacement as examples of indications for which IA hyaluronate is considered unproven and not medically necessary due to insufficient evidence of efficacy. Documentation supporting lack of benefit from randomized trials for hip OA (including a placebo RCT showing no difference at 3 months) underpins this determination.

The National Institute for Health and Care Excellence (NICE) guidance (2014) recommends that intra‑articular hyaluronan injections should not be offered for the management of osteoarthritis. This guidance is cited to support caution and may be used as a rationale when denying IA‑HA for OA indications where high‑quality evidence is lacking.

Sodium hyaluronate preparations used to improve skin appearance—such as filling contours, acne scars, or wrinkles—are considered cosmetic because these conditions are not functional impairments. The policy states that hyaluronic acid gel preparations for skin contouring, acne, scars, or wrinkle treatment are cosmetic procedures and are excluded from medical coverage.

This Medical Benefit Drug Policy explicitly does not apply to the state of Nebraska; the Policy History notes the addition of language excluding Nebraska and archives the prior policy version.

Use of intra‑articular hyaluronan injections for any indication other than knee osteoarthritis is considered unproven and not medically necessary in the absence of sufficient evidence of efficacy. The policy indicates IA‑HA for non‑knee joints is generally not supported and such requests may be denied unless compelling, well‑documented clinical rationale is provided.

The classification of IA‑HA as not medically necessary for hip and ankle osteoarthritis is supported by controlled trials and systematic reviews showing no consistent superiority to placebo. For hip OA, a multicenter placebo randomized controlled trial reported no difference in pain at 3 months between HA and placebo. For ankle OA, Cochrane‑level review authors concluded the available RCTs are low quality and insufficient to support benefit.

Major clinical guidelines and evidence syntheses do not support routine use of intra‑articular hyaluronic acid in many OA scenarios. The American College of Rheumatology conditionally recommends against IA‑HA for knee and first CMC joint OA and strongly recommends against use for hip OA; the American Academy of Orthopaedic Surgeons does not support routine viscosupplementation for knee OA and its guideline does not recommend HA for routine use.

Coding and Product Listings

Procedure CPT codesCPT

20605	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; without ultrasound guidance.
20606	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; with ultrasound guidance; with permanent recording and reporting.
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa; without ultrasound guidance.
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting.

HCPCS drug codesHCPCS

J7318	Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg.
J7320	Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg.
J7321	Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose.
J7322	Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg.
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose.
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose.
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg.
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose.
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose.
J7328	Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg.

1–10 of 14

1/2

Diagnosis ICD-10 codesICD-10

M17.0	Bilateral primary osteoarthritis of knee.
M17.10	Unilateral primary osteoarthritis, unspecified knee.
M17.11	Unilateral primary osteoarthritis, right knee.
M17.12	Unilateral primary osteoarthritis, left knee.
M17.2	Bilateral post-traumatic osteoarthritis of knee.
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee.
M17.31	Unilateral post-traumatic osteoarthritis, right knee.
M17.32	Unilateral post-traumatic osteoarthritis, left knee.
M17.4	Other bilateral secondary osteoarthritis of knee.
M17.5	Other unilateral secondary osteoarthritis of knee.

1–10 of 12

1/2

No explicit CPT/HCPCS/ICD codes listed in this partmixed

No codes listed

FDA-labeled HA products (by brand)mixed

product list	Hyalgan; Synvisc; Euflexxa; Supartz; Orthovisc; Synvisc One; Gel-One; Monovisc; Gelsyn-3; GenVisc 850; Hymovis; Durolane; Visco-3; TriVisc; Synojoynt; Triluron
cosmetic products	Restylane; Perlane; Hylaform; Juvéderm 24HV/30/30HV

inv-18: Minimum conservative therapy duration — key value (≥ 3 months)

Minimum conservative therapy durationAt least 3 months of conservative therapy (e.g., physical therapy or pharmacotherapy such as NSAIDs, acetaminophen, topical capsaicin) or intra‑articular steroid without functional improvement — unless intolerant

Acceptable conservative therapiesPhysical therapy, NSAIDs, acetaminophen, topical capsaicin, or intra‑articular corticosteroid injection

Documentation requiredRecord duration (≥3 months) and lack of functional improvement or documented intolerance to conservative therapy

inv-19: Minimum interval between courses — key value (≥ 6 months)

Minimum interval between courses

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization

Prior Authorization Required and Authorization Length

Prior authorization is required for intra-articular sodium hyaluronate injection courses for knee osteoarthritis. Initial authorization is for a single injection course per joint for 6 months (see FDA‑labeled dosing for product-specific course lengths). Reauthorization/continuation is allowed for a single injection course per joint for 6 months when criteria for response and timing are met.

Initial authorization: single injection course once per joint for 6 months
Reauthorization: single injection course once per joint for 6 months; at least 6 months must have passed since the prior course and documentation of prior clinical benefit is required

Prior Authorization

Prior Authorization for Intra‑articular Hyaluronate

Prior authorization is generally required when intra‑articular hyaluronate is requested and should be consistent with FDA‑labeled regimens. Documentation should include diagnosis, prior therapies and response, and dosing per the FDA labeling for the specific product.

Document diagnosis of knee osteoarthritis

Background and Clinical Context

Sodium hyaluronate (hyaluronic acid) is a naturally occurring component of synovial fluid used in intra‑articular injections to supplement joint lubrication and shock absorption. Products vary by molecular weight and degree of cross‑linking and are intended to augment synovial fluid properties to improve pain and function in osteoarthritis.

Definitions and Product References

inv-42: Sodium hyaluronate (HA) — definition and product variability (molecular weight, cross-linking)

DefinitionSodium hyaluronate (hyaluronic acid, HA) is a normal component of synovial fluid used in intra‑articular injections to supplement lubrication and absorb shock

Product variabilityCommercial HA products differ by molecular weight and cross‑linking and may be derived from bacterial fermentation or avian sources

Regulatory statusHA preparations are FDA‑approved as devices for treatment of knee osteoarthritis in patients who have failed conservative therapy

inv-43: Conservative therapy — definition (PT, pharmacotherapy, topical agents, IA steroid)

DefinitionConservative therapy refers to non‑surgical treatments such as physical therapy or pharmacotherapy (e.g., NSAIDs, acetaminophen, topical capsaicin) and may include intra‑articular corticosteroid injection

Policy Revision History and Changes

2026-01-01operationalLatest

Policy updated to exclude applicability to the state of Nebraska and prior policy version CS2025D0081N was archived.

Package inserts for FDA‑labeled hyaluronic acid products are listed in the references and include branded product inserts such as GenVisc 850, Hymovis, Durolane, Visco‑3, TriVisc, Synojoynt, Triluron, Euflexxa and others. These package inserts are the source of product‑specific dosing regimens referenced elsewhere in the policy.

Policy Summary

PayerUnitedHealthcare

PolicySodium Hyaluronate (intra‑articular) for knee osteoarthritis

Policy CodePolicy CS2026D0081O

Change TypeState applicability update (Nebraska excluded)

Effective DateJan 1, 2026

Next Review Date

Key ActionSubmit prior authorization with documentation of diagnosis, ≥3 months of conservative therapy (or intolerance), and product-specific regimen to request coverage for a 6‑month course.

SourceLink

On This Page

Systematic reviews and small RCTs are low quality and insufficient to support benefit; Cochrane review concluded data are insufficient to form guideline recommendations.

insufficient evidence

Coverage is discretionary; require prior authorization and documentation of failed conservative care.

Temporomandibular Joint (TMJ): Some RCTs and reviews report potential benefit for pain and function but HA has not consistently shown superiority to other active treatments; protocols vary and evidence is limited.insufficient for routine coverage

Consider only in context of clinical trials or when alternatives exhausted; require documentation of prior therapies.

Rheumatoid arthritis / other non‑knee joints: Small trials and pilot RCTs show short‑term improvements in some studies but overall evidence is limited and inconsistent.limited evidence

Coverage may be considered selectively with prior authorization and documentation of failed standard management.

Glottic (vocal fold) insufficiency / unilateral vocal fold paralysis (UVFP): Randomized and prospective studies report improvements in voice outcomes and quality of life after intracordal HA injections; effects are typically temporary (approximately 4–6 months) and complication rates are low.evidence supports short‑term benefit

Coverage may be allowed for temporary medialization in UVFP when performed by qualified specialists with documented voice impairment and consideration of alternatives.

At least 6 months must have passed since the prior course for the respective joint before reauthorization

Reauthorization conditionDocumentation of positive clinical response to prior injections and recurrence of pain required for repeat course

Continuing authorization lengthContinuing authorization is for a single injection course once per joint for 6 months

inv-20: Pain VAS threshold referenced in trial — key value (> 40 mm)

Pain VAS threshold referenced in hip trial> 40 mm on a visual analog scale

Use of VAS in documentationStudies commonly require documented pain scores (e.g., VAS >40 mm) to support clinical necessity

Context of thresholdReferenced in a placebo RCT of hip OA eligibility criteria (Richette et al., 2009)

inv-21: Product-specific injection regimen — key value listing exact approved injection counts per product

DurolaneCourse of treatment per joint = 1 injection

EuflexxaCourse of treatment per joint = 3 injections

HyalganCourse of treatment per joint = 5 injections

Synvisc / Synvisc OneSynvisc = 3 injections; Synvisc One = 1 injection

Gel-One, MonoviscGel-One = 1 injection; Monovisc = 1 injection

GenVisc 850, Supartz, Orthovisc, Gelsyn-3, Hymovis, Visco-3, TriVisc, Synojoynt, TriluronGenVisc 850 = 3–5 injections; Supartz = 3–5 injections; Orthovisc = 3–4 injections; Gelsyn-3 = 3 injections; Hymovis = 2 injections; Visco-3 = 3 injections; TriVisc = 3 injections; Synojoynt = 3 injections; Triluron = 3 injections

Document prior conservative therapy and duration (or intolerance) and prior response to HA if applicable

Follow FDA‑labeled dosing per product (e.g., Durolane = 1 injection; Euflexxa = 3 injections; Hyalgan = 5 injections; see product table)

Prior Authorization

Prior Authorization Depends on Plan Terms

Applicability of this prior authorization requirement and any specific operational rules depend on the member’s federal, state, or contractual benefit plan. Always verify member benefit terms before assuming coverage.

If federal, state, or contractual benefit terms conflict with this policy, the benefit terms govern
Providers should check benefit plan requirements prior to using this policy

Documentation Required

Conservative Therapy Requirement Before Hyaluronate

Conservative non‑surgical therapy is required prior to intra‑articular hyaluronate for knee osteoarthritis. Conservative therapy includes physical therapy and pharmacotherapy (e.g., NSAIDs, acetaminophen, topical agents) and/or intra‑articular corticosteroid injection when appropriate. A minimum of approximately 3 months of adequate conservative therapy is expected unless the member is unable to tolerate or has contraindications.

Conservative measures: physical therapy, NSAIDs, acetaminophen, topical capsaicin, and/or intra‑articular steroid injection where appropriate
Documentation of ≥3 months of inadequate response to conservative therapy or intolerance is expected for initial authorization

Denial Risk

Insufficient Evidence for Many Non‑Knee Indications May Trigger Denial

Evidence for many non‑knee joint indications (hip, ankle, TMJ, etc.) is limited or conflicting and may be insufficient to support coverage. Guidance documents (e.g., NICE, VA/DoD, ACR, AAOS) and systematic reviews often do not recommend routine use of IA hyaluronate for these joints. Requests for non‑knee indications may be denied based on insufficient evidence.

Hip, ankle, TMJ and other non‑knee indications: generally insufficient high‑quality evidence to support efficacy
NICE guidance and other guidelines often advise against offering IA hyaluronan for some non‑knee OA indications

Denial Risk

Contraindications and Cosmetic Exclusion

Do not administer sodium hyaluronate to patients with known hypersensitivity to hyaluronate preparations or to avian‑derived products (unless product labeling excludes this contraindication, e.g., Orthovisc). Do not inject into joints with infection or skin disease at the injection site. Use for non‑functional cosmetic indications (e.g., skin contours, wrinkle augmentation) is considered cosmetic and not covered.

Contraindications: allergy to hyaluronate or avian/avian‑derived products (except as noted for specific products)
Contraindications specific to Orthovisc: hypersensitivity to gram‑positive bacterial proteins
Do not inject if infection or skin disease is present at the injection site
Cosmetic uses (skin contours, wrinkle filling) are not covered

Step Therapy

Preferred Product Step Therapy

Step therapy / preferred product requirements apply in many jurisdictions: Durolane, Euflexxa, and Gelsyn‑3 are preferred products. Coverage of other named products (e.g., GenVisc 850, Hyalgan, Supartz, Orthovisc, Synvisc, etc.) typically requires documentation of trial and inadequate response to the preferred products or documentation of contraindication/intolerance.

Preferred products: Durolane, Euflexxa, Gelsyn‑3
Non‑preferred products require documented trial and inadequate response to the preferred products OR documented contraindication/intolerance to the preferred products

Step Therapy

Step Therapy and Guideline Considerations

Guideline and evidence‑based considerations favor alternative intra‑articular treatments (such as corticosteroid injections) over hyaluronate in many scenarios; use of HA should follow shared decision‑making and consideration of higher‑quality evidence favoring steroids for short‑term relief. Step therapy policies may require trial of recommended alternatives before HA.

ACR and AAOS guidance generally favor IA glucocorticoid injections over HA for many patients
Step therapy may require trial/failure of corticosteroid injections or other recommended alternatives prior to covering HA

Conservative therapy should be tried at adequate dose/duration (at least 3 months) unless the patient is intolerant

Role in authorizationDocumentation of failed conservative therapy is required for initial authorization of IA HA for knee OA

inv-44: Intra‑articular hyaluronate (HA) — definition and intended clinical effect

DefinitionIntra‑articular hyaluronate (HA) are purified hyaluronic acid/hylan preparations injected into a joint space intended to improve pain and function by augmenting synovial fluid properties

Intended clinical effectActs mechanically to supplement lubrication and shock absorption in osteoarthritic joints, aiming to reduce pain and improve function

Regulatory noteFDA labeling is currently limited to knee osteoarthritis for most IA HA products

inv-45: Intracordal (injectable laryngoplasty) hyaluronate — definition and vocal fold medialization use

DefinitionIntracordal (injectable laryngoplasty) hyaluronate is injection of HA into the vocal fold for medialization to improve glottic closure and voice in unilateral vocal fold paralysis or other glottic insufficiency

Clinical useUsed for temporary medialization with reported durability often around 4–6 months depending on product particle size and cross‑linking

EvidenceMultiple small randomized and prospective studies report improved voice outcomes and quality of life after intracordal HA injections

inv-47: Injection laryngoplasty (IL) — definition and indications

DefinitionInjection laryngoplasty (IL) is the procedure of injecting a material (e.g., hyaluronate) into the vocal fold to medialize it and improve glottic insufficiency and voice quality

IndicationsCommonly used for unilateral vocal fold paralysis (UVFP), presbyphonia, scar, sulcus, or atrophy where temporary medialization is desired

Durability and considerationsParticle size and product formulation affect durability; some studies report improved VHI and objective voice measures up to 6 months or longer

inv-46: Viscosupplementation — definition (mechanical lubricant function)

DefinitionViscosupplementation refers to intra‑articular injection of sodium hyaluronate intended to act mechanically as a lubricant to reduce pain from osteoarthritis

MechanismFunctions primarily by augmenting synovial fluid viscosity and lubrication rather than systemic drug absorption

Regulatory noteA number of HA preparations have FDA PMA approval for viscosupplementation of the knee under product code MOZ

inv-48: Product package inserts — references for branded intra-articular hyaluronic acid products (package inserts)

Select package inserts (examples)GenVisc 850; Hymovis; Durolane; Visco-3; TriVisc; Synojoynt; Triluron; Euflexxa; (full list in References) — see individual product package inserts for labeled dosing and precautions

Purpose of insertsPackage inserts provide product‑specific FDA labeling, dosing per course, contraindications, and safety information

Location in policyPackage insert references are listed in the References section of the policy (see numbered list)

inv-49: Clinical guideline reference — AAOS guideline summary citation for management of knee osteoarthritis (nonarthroplasty)

CitationBrophy RH, Fillingham YA. AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition. J Am Acad Orthop Surg. 2022;30(9):e721-e729.

Guideline scopeAAOS guideline provides evidence-based recommendations for management of knee osteoarthritis, including nonarthroplasty options

Relevance to policyAAOS guidance is cited in the policy as a clinical guideline reference informing recommendations and coverage considerations for knee OA